Etienne Brain
Vice President for Healthcare Outcomes Policy and
Oncology and Molecular Radiation Sciences
University of Boston
Norway
Biography
Etienne GC Brain, MD PhD, has been working since 1998 as a medical oncologist at the Hôpital René Huguenin (Saint-Cloud, France), which is now part of the academic centre Institut Curie. He obtained both his MD and PhD from University Paris V René Descartes after leading works in preclinical and clinical pharmacology on alkylating agents in Boston (Dana Farber Cancer Institute and Boston University). He was the Deputy Director for Research at Centre René Huguenin from 2008-2009, until the merge with Institut Curie happened in 2010, making this "multi-sites” institution one of the largest one dedicated to breast cancer management in Europe. Etienne GC Brain, MD PhD, has been working since 1998 as a medical oncologist at the Hôpital René Huguenin (Saint-Cloud, France), which is now part of the academic centre Institut Curie. He obtained both his MD and PhD from University Paris V René Descartes after leading works in preclinical and clinical pharmacology on alkylating agents in Boston (Dana Farber Cancer Institute and Boston University). He was the Deputy Director for Research at Centre René Huguenin from 2008-2009, until the merge with Institut Curie happened in 2010, making this "multi-sites” institution one of the largest one dedicated to breast cancer management in Europe.
Research Interest
Etienne GC Brain is the secretary of the Breast Cancer Group of EORTC and chairs the GERICO group (clinical research in geriatric oncology) at UNICANCER. He is very committed to clinical research, involved in many trials covering breast cancer and geriatric oncology. His most recent interest focuses on competing risks for mortality in older breast cancer patients, trying to better define the indication of systemic treatment in adjuvant setting, and is embodied in the national program ASTER 70s granted in 2011 by the French health ministry. He is (co)author of several publications in peer-reviewed journals, including the JAMA, Lancet Oncol and J Clin Oncol.